SCOTUS to hear biosimilar clash between Amgen and Sandoz
25-04-2017
AVNphotolab / iStockphoto.com
The US Supreme Court heard oral arguments from Amgen and Sandoz yesterday in the ongoing battle over a biosimilar version of Amgen’s Neupogen (filgrastim).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
SCOTUS, Amgen, Sandoz, BPCIA, patent, biosimilar, biologics, FDA, Federal Circuit
